Search results for "Bifidobacteria"
showing 6 items of 6 documents
Prebiotic Xylo-Oligosaccharides Ameliorate High-Fat-Diet-Induced Hepatic Steatosis in Rats
2020
Understanding the importance of the gut microbiota (GM) in non-alcoholic fatty liver disease (NAFLD) has raised the hope for therapeutic microbes. We have shown that high hepatic fat content associated with low abundance of Faecalibacterium prausnitzii in humans and, further, the administration of F. prausnitzii prevented NAFLD in mice. Here, we aimed at targeting F. prausnitzii by prebiotic xylo-oligosaccharides (XOS) to treat NAFLD. First, the effect of XOS on F. prausnitzii growth was assessed in vitro. Then, XOS was supplemented or not with high (HFD, 60% of energy from fat) or low (LFD) fat diet for 12 weeks in Wistar rats (n = 10/group). XOS increased F. prausnitzii growth, having onl…
Estrategias biotecnológicas para reducir el contenido en fitatos en productos fermentados de origen vegetal mediante fitasas de bifidobacterias
2015
Los alimentos integrales de origen vegetal, concretamente, los cereales de grano entero y leguminosas se caracterizan por ser una fuente excelente de fibra dietética y poseer un elevado contenido en compuestos fitoquímicos. Además de proporcionar macronutrientes, como carbohidratos complejos y proteínas, también destacan por su contenido en micronutrientes como son las vitaminas y minerales. Sin embargo, su ingesta conlleva a la vez un aporte en sustancias antinutritivas, como los fitatos, con gran afinidad por minerales, proteínas y elementos traza, que pueden comprometer su absorción por formación de quelatos estables en el tracto digestivo. Una hidrólisis o defosforilación parcial de los…
Linking Human Milk Oligosaccharides, Infant Fecal Community Types, and Later Risk To Require Antibiotics
2020
Human milk is the sole and recommended nutrition for the newborn infant and contains one of the largest constituents of diverse oligosaccharides, dubbed human milk oligosaccharides (HMOs). Preclinical and clinical association studies indicate that HMOs have multiple physiological functions largely mediated through the establishment of the gut microbiome. Until recently, HMOs were not available to investigate their role in randomized controlled intervention trials. To our knowledge, this is the first report on the effects of 2 HMOs on establishing microbiota in newborn infants. We provide a detailed description of the microbiota changes observed upon feeding a formula with 2 HMOs in comparis…
Mucosal immunology and probiotics.
2013
The cross-talk between the mucosa-associated immune system and microbiota is critical in mucosal tissue homeostasis as well as in protection against infectious and inflammatory diseases occurring at mucosal sites. This recent evidence has paved the way to therapeutic approaches aimed at modulating the mucosa-associated immune system using probiotics. Different strains of probiotics possess the ability to finely regulate dendritic cell (DC) activation, polarizing the subsequent T cell activity toward Th1 (e.g. Lactobacillus (Lb) acidophilus), Th2 (Lb.reuteri and Bifidobacterium bifidum) or, as more recently demonstrated, Th17 responses induced by specific strains such as Lb.rhamnosus GG and …
Development ofBifidobacterium lactis Bb 12 onβ-(2,6)-Linked Fructan-Containing Substrate
2004
β-(2,1)-linked fructan of plant origin (inulin) and the related oligosaccharides (FOS) as non-digestible carbohydrates, i.e., potent prebiotics, can stimulate the growth of various probiotic lactic acid bacteria, including a number of bifidobacteria strains. The related (3-(2,6)-linked fructans of microbial origin (levan and FOS), however, have scarcely been investigated in this respect. Therefore, the bifidogenic properties of various fructans, i.e., inulin, levan, fructooligosaccharides (FOS) and fructan syrup (FS), were tested as glucose substitutes in MRS media and were compared concerning their effect on the commercial strain Bifidobacterium lactis Bb 12. Although glucose was the prefe…
The long-term effects of probiotics in the therapy of ulcerative colitis: a clinical study
2016
Aim: Intestinal dysbiosis seems to be the leading cause of inflammatory bowel diseases, and probiotics seems to represent the proper support against their occurrence. Actually, probiotic blends and anti-inflammatory drugs represent a weapon against inflammatory bowel diseases. The present study evaluates the long-term (2 years) effects of combination therapy (mesalazine plus a probiotic blend of Lactobacillus salivarius, Lactobacillus acidophilus and Bifidobacterium bifidus strain BGN4) on ulcerative colitis activity. Method: Sixty patients with moderate-to-severe ulcerative colitis were enrolled: 30 of them were treated with a single daily oral administration of mesalazine 1200 mg; 30 pati…